Moxonidine

Phase 2Small molecule

SSolvay Pharmaceuticals

Moxonidine is one of 60 small molecule programs targeting Postural Tachycardia Syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Postural Tachycardia SyndromeActive, not recruiting

Postmenopausal WomenCompleted

ObesityRecruiting

Postural Tachycardia SyndromePhase 1

Active, not recruiting

Postmenopausal WomenPreclinical

Completed

ObesityPhase 2

Recruiting

Competition

Competitive Landscape

190 competitors in Obesity

#DrugCompanyPhaseTrials

Maridebart Cafraglutide

Amgen

Phase 3

7 2

Vivia

SSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Phase 3

1 3

Synthroid

IInstitut Jerome Lejeune

Phase 3

1 4

Enavogliflozin

Daewoong Pharmaceutical Co. LTD.

Phase 3

1 5

IBI362

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

4 6

Gemtesa

Sumitomo Pharma America, Inc.

Phase 3

1 7

Eloralintide

Eli Lilly

Phase 3

10 8

Mibavademab

Regeneron

Phase 3

2 9

Aleniglipron

GGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Phase 3

2 10

Moxonidine

SSolvay Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 1/2Recruiting

Obesity

NCT05312892

Clinical

Trials by Indication[1]

Obesity3 trials

Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity

Terminated·IItalo Biaggioni·Phase 1·NCT04329806·10 enrolled

Sympathetic Mechanisms in Obesity-Crossover Design

Recruiting·VVanderbilt University Medical Center·Phase 1/2·NCT05312892·12 enrolled

Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity

Unknown status·BBaker Heart and Diabetes Institute·Phase 4·NCT01180231·77 enrolled

Hypertension3 trials

Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension

Unknown status·RRoyal Perth Hospital·Phase 4·NCT04474899·120 enrolled

The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension

Unknown status·BBaker Heart and Diabetes Institute·Phase 4·NCT01360710·100 enrolled

Treatment of Adiposity Related hypErTension (TARGET)

Completed·UUMC Utrecht·Phase 4·NCT01138423·32 enrolled

Ischemia Reperfusion Injury1 trial

Role of Sympathetic Activation in Ischemia Reperfusion Injury

Completed·RRoyal Perth Hospital·Phase 4·NCT04479813·46 enrolled

Kidney Disease1 trial

Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease

Completed·BBaker Heart and Diabetes Institute·Phase 4·NCT01094769·48 enrolled

Polycystic Ovary Syndrome1 trial

Polycystic Ovary Syndrome - Improving Outcomes

Completed·BBaker Heart and Diabetes Institute·Phase 4·NCT01504321·42 enrolled

6 more indications

Completed·SSpyridon Deftereos·Phase 4·NCT01791699·150 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Moxonidine in Indian Patients

Completed·SSolvay Pharmaceuticals·Phase 3·NCT00160277·100 enrolled

Surgery1 trial

Moxonidine in Patients Undergoing Vascular Surgery

Terminated·UUniversity Hospital, Basel, Switzerland·Phase 3·NCT00244504·141 enrolled

Unspecified2 trials

Moxonidine Effects on Neuropeptide Y

Completed·—·Phase 4·NCT05147753·90 enrolled

Autonomic Determinants of POTS - Pilot1

Active, not recruiting·VVanderbilt University Medical Center·Phase 1·NCT04050410·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Moxonidine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Moxonidine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Moxonidine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Solvay Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSolvay Pharmaceuticals

Moxonidine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Obesity3 trials

Hypertension3 trials

Ischemia Reperfusion Injury1 trial

Kidney Disease1 trial

Polycystic Ovary Syndrome1 trial

Side Effects1 trial

Postmenopausal Women1 trial

Prevention1 trial

Efficacy and Safety1 trial

Surgery1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News